Catalyst
Slingshot members are tracking this event:
Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia Released
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RARE | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 06, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Krn23, X-linked Hypophosphatemia, Phase 2
